Vanda Pharmaceuticals Inc.
For the period ended Jun 4, 2026. Filed Apr 23, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 4, 2026 · Filed Apr 23, 2026
VNDA$3.82+6.4%Stored close · as of Nov 6, 2026
Contents
APPENDIX A - 2016 EQUITY INCENTIVE PLAN
2016 EQUITY INCENTIVE PLAN
(AMENDED AND RESTATED EFFECTIVE AS OF JUNE 11, 2020)
TABLE OF CONTENTS
| Page | ||
| ARTICLE 1. | INTRODUCTION | A-1 |
| ARTICLE 2. | ADMINISTRATION | A-1 |
| 2.1 | Committee Composition | A-1 |
| 2.2 | Committee Responsibilities | A-1 |
| 2.3 | Committee for Non-Officer Grants | A-1 |
| ARTICLE 3. | SHARES AVAILABLE FOR GRANTS | A-1 |
| 3.1 | Basic Limitation | A-1 |
| 3.2 | Shares Returned to Reserve | A-2 |
| ARTICLE 4. | ELIGIBILITY | A-2 |
| 4.1 | Incentive Stock Options | A-2 |
| 4.2 | Other Grants | A-2 |
| ARTICLE 5. | OPTIONS | A-2 |
| 5.1 | Stock Option Agreement | A-2 |
| 5.2 | Number of Shares | A-2 |
| 5.3 | Exercise Price | A-2 |
| 5.4 | Exercisability and Term | A-2 |
| 5.5 | Effect of Change in Control | A-2 |
| 5.6 | Modification or Assumption of Options | A-2 |
| 5.7 | Voting and Dividend Rights | A-3 |
| ARTICLE 6. | PAYMENT FOR OPTION SHARES | A-3 |
| 6.1 | General Rule | A-3 |
| 6.2 | Surrender of Stock | A-3 |
| 6.3 | Exercise/Sale | A-3 |
| 6.4 | Promissory Note | A-3 |
| 6.5 | Other Forms of Payment | A-3 |
| ARTICLE 7. | STOCK APPRECIATION RIGHTS | A-3 |
| 7.1 | SAR Agreement | A-3 |
| 7.2 | Number of Shares | A-3 |
| 7.3 | Exercise Price | A-3 |
| 7.4 | Exercisability and Term | A-3 |
| 7.5 | Effect of Change in Control | A-4 |
| 7.6 | Exercise of SARs | A-4 |
| 7.7 | Modification or Assumption of SARs | A-4 |
| 7.8 | Voting and Dividend Rights | A-4 |
| ARTICLE 8. | RESTRICTED SHARES | A-4 |
| 8.1 | Restricted Stock Agreement | A-4 |
| 8.2 | Payment for Awards | A-4 |
| 8.3 | Vesting Conditions | A-4 |
A-i
| Page | ||
| 8.4 | Voting and Dividend Rights | A-4 |
| ARTICLE 9. | STOCK UNITS | A-5 |
| 9.1 | Stock Unit Agreement | A-5 |
| 9.2 | Payment for Awards | A-5 |
| 9.3 | Vesting Conditions | A-5 |
| 9.4 | Voting and Dividend Rights | A-5 |
| 9.5 | Form and Time of Settlement of Stock Units | A-5 |
| 9.6 | Death of Recipient | A-5 |
| 9.7 | Creditors’ Rights | A-5 |
| ARTICLE 10. | PROTECTION AGAINST DILUTION | A-5 |
| 10.1 | Adjustments | A-6 |
| 10.2 | Dissolution or Liquidation | A-6 |
| 10.3 | Reorganizations | A-6 |
| ARTICLE 11. | AWARDS UNDER OTHER PLANS | A-7 |
| ARTICLE 12. | PAYMENT OF DIRECTOR’S FEES IN SECURITIES | A-7 |
| 12.1 | Effective Date | A-7 |
| 12.2 | Elections to Receive NSOs, Restricted Shares or Stock Units | A-7 |
| 12.3 | Number and Terms of NSOs, Restricted Shares or Stock Units | A-7 |
| ARTICLE 13. | LIMITATION ON RIGHTS | A-7 |
| 13.1 | Retention Rights | A-7 |
| 13.2 | Stockholders’ Rights | A-7 |
| 13.3 | Regulatory Requirements | A-7 |
| 13.4 | Transferability of Awards | A-7 |
| ARTICLE 14. | TAXES | A-8 |
| 14.1 | General Withholding Obligations | A-8 |
| 14.2 | Share Withholding | A-8 |
| 14.3 | Code Section 409A Matters | A-8 |
| ARTICLE 15. | LIMITATION ON PAYMENTS | A-8 |
| 15.1 | Scope of Limitation | A-8 |
| 15.2 | Basic Rule | A-8 |
| 15.3 | Reduction of Payments | A-8 |
| 15.4 | Overpayments and Underpayments | A-9 |
| 15.5 | Related Corporations | A-9 |
| ARTICLE 16. | FUTURE OF THE PLAN | A-9 |
| 16.1 | Term of the Plan | A-9 |
| 16.2 | Amendment or Termination | A-9 |
| 16.3 | Stockholder Approval | A-9 |
A-ii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.